Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Catalyst Health Solutions, Inc. (“Catalyst” or the “Company”) (Nasdaq: CHSI) relating to the proposed acquisition by SXC Health Solutions Corporation. (“SXC”). Under the terms of the transaction, Catalyst shareholders would receive only $28.00 in cash and 0.6606 shares of SXC for each share of Catalyst stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Catalyst for not acting in the Company’s shareholders' best interests in connection with the sale process to SXC. If you own shares of Catalyst stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org visiting http://brodsky-smith.com/413-chsi-catalyst-health-solutions-inc.html, or by calling toll free 877-LEGAL-90.
Catalyst Health Solutions (Nasdaq:CHSI) hit a new 52-week high Monday as it is currently trading at $96.59, above its previous 52-week high of $96.41 with 178,069 shares traded as of 10:55 a.m. ET. Average volume has been 862,700 shares over the past 30 days.
Catalyst Health Solutions (Nasdaq:CHSI) hit a new 52-week high Monday as it is currently trading at $92.63, above its previous 52-week high of $92.62 with 358,408 shares traded as of 1:30 p.m. ET. Average volume has been 833,500 shares over the past 30 days.